Gilead Sciences said Thursday its total revenues were $5.3 billion in 2019 compared to $5.1 billion in 2018, with net income of $2.0 billion compared to $1.5 billion in 2018.
Gilead said its non-GAAP net income was $2.3 billion or $1.76 per diluted share in 2019 compared to $2.0 billion or $1.48 per diluted share in 2018.
According to the press release, total product sales for the first quarter of 2019 were $5.2 billion compared to $5.0 billion for the same period in 2018. Product sales for the first quarter of 2019 were $3.8 billion in the United States, $882 million in Europe and $522 million in other locations. Product sales for the first quarter of 2018 were $3.5 billion in the United States, $1.0 billion in Europe and $469 million in other locations., the company said.